Valéria Cristina Resende Aguiar

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro et al. · The Lancet · 2021 · 245 citations · Full text

Thrombosis, Hematology, Patient Safety +8

Zika and Chikungunya Virus and Risk for Venous Thromboembolism

Eduardo Ramacciotti, Leandro Barile Agati, Valéria Cristina Resende Aguiar et al. · Clinical and Applied Thrombosis/Hemostasis · 2019 · 53 citations · Full text

Thrombosis, Pulmonary Embolism, Deep Venous Thrombosis +12

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial

André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, Leandro Barile Agati et al. · Clinical and Applied Thrombosis/Hemostasis · 2022 · 28 citations · Full text

Surgical Oncology, Direct Oral Anticoagulants, Pharmacotherapy +17

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial

Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro et al. · American Heart Journal · 2021 · 19 citations · Full text

Thrombosis, Treatment And Prevention, Patient Safety +7

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

Lívia Pimenta Bonifácio, Eduardo Ramacciotti, Leandro Barile Agati et al. · Revista da Sociedade Brasileira de Medicina Tropical · 2023 · 11 citations · Full text